(Q38946774)

7 September 2017

title

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial (English)

1 reference

7 September 2017

main subject

phase II clinical trial

0 references

0 references

1 reference

1 reference

10

1 reference

7 September 2017

5

Tjalf Ziemssen

1 reference

7 September 2017

2

Laura Balcer

1 reference

7 September 2017

3

Steven Galetta

1 reference

7 September 2017

Ludo J. Vanopdenbosch

6

object named as

Ludo Vanopdenbosch

1 reference

7 September 2017

Diego Cadavid

1

1 reference

7 September 2017

Orhan Aktas

4

1 reference

7 September 2017

Jette Frederiksen

7

1 reference

7 September 2017

Mark Skeen

8

1 reference

7 September 2017

Glenn J Jaffe

9

1 reference

7 September 2017

Focke Ziemssen

11

1 reference

7 September 2017

Luca Massacesi

12

1 reference

7 September 2017

Yi Chai

13

1 reference

7 September 2017

Lei Xu

14

1 reference

7 September 2017

Stefanie Freeman

15

1 reference

7 September 2017

RENEW Study Investigators

16

1 reference

7 September 2017

publication date

15 February 2017

1 reference

7 September 2017

1 reference

7 September 2017

volume

16

1 reference

7 September 2017

issue

3

1 reference

7 September 2017

page(s)

189-199

1 reference

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

LINGO-1 negatively regulates myelination by oligodendrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Acute optic neuritis: Unmet clinical needs and model for new therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Recovery of vision and pupil responses in optic neuritis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Re-evaluating the treatment of acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Remyelination of optic nerve lesions: spatial and temporal factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Latency delay of visual evoked potential is a real measurement of demyelination in a rat model of optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Myelin deficiencies visualized in vivo: visually evoked potentials and T2-weighted magnetic resonance images of shiverer mutant and wild-type mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Visual evoked potentials and MBP gene expression imply endogenous myelin repair in adult rat optic nerve and chiasm following local lysolecithin induced demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Recovery from optic neuritis: an ROI-based analysis of LGN and visual cortical areas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Serial visual evoked potentials in 90 untreated patients with acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Nogo receptor inhibition enhances functional recovery following lysolecithin-induced demyelination in mouse optic chiasm

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Simvastatin improves final visual outcome in acute optic neuritis: a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Long-term recovery and fellow eye deterioration after optic neuritis, determined by serial visual evoked potentials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Neurophysiological evidence for long-term repair of MS lesions: implications for axon protection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Variation of visual evoked potential delay to stimulation of central, nasal, and temporal regions of the macula in optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Demyelination affects temporal aspects of perception: an optic neuritis study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Ganglion cell loss in relation to visual disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930377-5

7 January 2021

10.1016/S1474-4422(16)30377-5

Identifiers

DOI

1 reference

7 September 2017

1 reference